VX17-445-102 Efficacy and Safety of VX-445/TEZ/IVA in CF Het-min

Details

Therapeutic category
Restore CFTR Function
Trial status
Completed Participating Centres
Phase
Phase III

Full title

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Trial Reference Number
108763
Trial type
Medication
Intervention
CFTR Modulators
Recruitment target
360
Last edited date
27/06/2019
CF sponsor
Vertex Pharmaceuticals Incorporated
CF sponsor type
Commercial

Who can take part?

Top inclusion criteria
  • Age 12 Years and older
  • Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
  • FEV1 above or equal to 40% and below or equal to 90%

Your donation will make a difference:

Select amount